Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

140
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
140
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TNFα signaling in radiation-induced chronic bowel dysfunction suggests therapeutic potential for IBD biologics.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Ageing promotes metastasis via activation of the integrated stress response.

Nature·2026
Same author

Solving the limited availability of Astatine-211 from a European perspective: from production to the end user.

EJNMMI radiopharmacy and chemistry·2026
Same author

Spontaneous association of different forms of non-conjugated astatine-211 to serum albumin.

Nuclear medicine and biology·2026
Same author

Novel PSMA targeting alpha-emitting radioligand [<sup>211</sup>At]PSAt-3-Ga inhibits tumor growth and increases survival in a preclinical model of human xenograft prostate cancer.

EJNMMI research·2026
Same author

Brain metastasis in stage IV lung adenocarcinoma is frequently missed by symptom-based screening.

Discover oncology·2025

Related Experiment Video

Updated: Aug 13, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K

Astatine-211 based radionuclide therapy: Current clinical trial landscape.

Per Albertsson1,2, Tom Bäck3, Karin Bergmark1,2

  • 1Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Frontiers in Medicine
|January 23, 2023
PubMed
Summary

Astatine-211 (211At) shows promise for targeted alpha therapy (TAT) due to its alpha-particle emitting properties. This review summarizes completed and ongoing clinical trials, exploring future directions for this cancer treatment modality.

Keywords:
alpha particleastatine-211clinical trialhumanradionuclidetargeted alpha therapy

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

507
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Related Experiment Videos

Last Updated: Aug 13, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.0K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

507
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical therapy
  • Oncology

Background:

  • Astatine-211 (211At) possesses advantageous physical characteristics for targeted alpha therapy (TAT).
  • TAT utilizes alpha-emitting radionuclides to deliver high-energy radiation directly to cancer cells.
  • 211At is a leading candidate radionuclide for clinical application in TAT.

Purpose of the Study:

  • To review the clinical efficacy and safety of Astatine-211 in targeted alpha therapy.
  • To provide an overview of completed and ongoing clinical trials involving 211At.
  • To discuss the future potential and challenges of 211At-based TAT.

Main Methods:

  • Systematic review of completed clinical trials.
  • Analysis of data from ongoing clinical investigations.
  • Discussion of preclinical and clinical research findings.

Main Results:

  • Summary of key outcomes from completed 211At TAT clinical trials.
  • Presentation of current progress and preliminary results from ongoing studies.
  • Identification of therapeutic benefits and potential toxicities observed.

Conclusions:

  • 211At demonstrates significant potential as a therapeutic radionuclide for targeted alpha therapy.
  • Further clinical trials are essential to fully establish the role of 211At in cancer treatment.
  • Ongoing research and development are crucial for optimizing 211At-based therapies.